Petta Dalila, D'Arrigo Daniele, Salehi Shima, Talò Giuseppe, Bonetti Lorenzo, Vanoni Marco, Deabate Luca, De Nardo Luigi, Dubini Gabriele, Candrian Christian, Moretti Matteo, Lopa Silvia, Arrigoni Chiara
Regenerative Medicine Technologies Lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa, 5, 6500, Bellinzona, Switzerland.
Service of Orthopaedics and Traumatology, Department of Surgery, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland.
Mater Today Bio. 2024 May 6;26:101072. doi: 10.1016/j.mtbio.2024.101072. eCollection 2024 Jun.
Osteoarthritis (OA) is a highly disabling pathology, characterized by synovial inflammation and cartilage degeneration. Orthobiologics have shown promising results in OA treatment thanks to their ability to influence articular cells and modulate the inflammatory OA environment. Considering their complex mechanism of action, the development of reliable and relevant joint models appears as crucial to select the best orthobiologics for each patient. The aim of this study was to establish a microfluidic OA model to test therapies in a personalized human setting. The joint-on-a-chip model included cartilage and synovial compartments, containing hydrogel-embedded chondrocytes and synovial fibroblasts, separated by a channel for synovial fluid. For the cartilage compartment, a Hyaluronic Acid-based matrix was selected to preserve chondrocyte phenotype. Adding OA synovial fluid induced the production of inflammatory cytokines and degradative enzymes, generating an OA microenvironment. Personalized models were generated using patient-matched cells and synovial fluid to test the efficacy of mesenchymal stem cells on OA signatures. The patient-specific models allowed monitoring changes induced by cell injection, highlighting different individual responses to the treatment. Altogether, these results support the use of this joint-on-a-chip model as a prognostic tool to screen the patient-specific efficacy of orthobiologics.
骨关节炎(OA)是一种极具致残性的病理状况,其特征为滑膜炎症和软骨退变。由于其能够影响关节细胞并调节骨关节炎的炎症环境,骨科生物制剂在骨关节炎治疗中已显示出有前景的结果。考虑到其复杂的作用机制,建立可靠且相关的关节模型对于为每位患者选择最佳的骨科生物制剂而言显得至关重要。本研究的目的是建立一种微流控骨关节炎模型,以便在个性化的人体环境中测试治疗方法。芯片上关节模型包括软骨和滑膜腔室,其中含有水凝胶包埋的软骨细胞和滑膜成纤维细胞,由一个用于滑液的通道隔开。对于软骨腔室,选择了基于透明质酸的基质来维持软骨细胞表型。添加骨关节炎滑液会诱导炎性细胞因子和降解酶的产生,从而形成骨关节炎微环境。使用患者匹配的细胞和滑液生成个性化模型,以测试间充质干细胞对骨关节炎特征的疗效。患者特异性模型能够监测细胞注射所诱导的变化,突出了不同个体对治疗的反应。总之,这些结果支持将这种芯片上关节模型用作一种预后工具,以筛选骨科生物制剂的患者特异性疗效。